Aspergillus-specific IgM/IgG antibody serostatus of patients hospitalized with moderate-critical COVID-19 in Uganda

Abstract

Invasive pulmonary aspergillosis is known to complicate the coronavirus diseases-2019 (COVID-19), especially those with criticalillness. We investigated the baseline anti-Aspergillus antibody serostatus of patients with moderate-critical COVID-19 hospitalizedat 3 COVID-19 Treatment Units in Uganda. All 46 tested patients, mean age 30, and 11% with underlying respiratorydisease had a negative serum anti-Aspergillus IgM/IgG antibody immunochromatographic test on day 3 (mean) of symptomonset (range 1-26), but follow up specimens to assess seroconversion were not available.
 Keywords: Invasive pulmonary aspergillosis; COVID-19; critical illness; Uganda.

Editorial I: So, who wins? It is still: NCDs 3; Infections 2

“…They include themes on cancer, [13][14][15][16][17][18][19][20][21][22][23][24] diabetes mellitus, [25][26][27][28][29] respiratory and cardiovascular illnesses, [30][31][32][33][34][35] and others. [36][37][38][39][40][41][42] The non-communicable diseases theme is then followed by infectious diseases, ranging from HIV, [43][44][45][46][47][48][49] the COVID-19 pandemic, [50][51][52][53][54][55][56][57] and others. [58][59][60][61][62][63][64][65][66] We conclude the issue with a hybrid of papers [67][68]…”